Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies

CONCLUSION: With nearly 5 years of emicizumab exposure across the HAVEN 3 and 4 studies in people with HA without inhibitors, these data indicate continued bleed control with no new safety signals observed during long-term follow-up.PMID:38559572 | PMC:PMC10978536 | DOI:10.1016/j.rpth.2024.102364

Source: Thrombosis and Haemostasis - April 1, 2024 Category: Hematology Authors: Johnny Mahlangu V íctor Jiménez-Yuste Giuliana Ventriglia Markus Niggli Simona Barlera C édric Hermans Michaela Lehle Pratima Chowdary Lyle Jew Jerzy Windyga Laurent Frenzel Christophe Schmitt Giancarlo Castaman Steven W Pipe Source Type: research